See more : Bellerophon Therapeutics, Inc. (BLPH) Income Statement Analysis – Financial Results
Complete financial analysis of Leap Therapeutics, Inc. (LPTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Leap Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Jio Financial Services Limited (JIOFIN.NS) Income Statement Analysis – Financial Results
- Eris Lifesciences Limited (ERIS.BO) Income Statement Analysis – Financial Results
- Fiducial Real Estate SA (ORIA.PA) Income Statement Analysis – Financial Results
- TGS International Ltd. (TGSI) Income Statement Analysis – Financial Results
- Chindata Group Holdings Limited (CD) Income Statement Analysis – Financial Results
Leap Therapeutics, Inc. (LPTX)
About Leap Therapeutics, Inc.
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.50M | 1.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 427.00K | 415.00K | 0.00 | 0.00 | 776.00K | 49.00K | 48.00K | 25.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -427.00K | -415.00K | 1.50M | 1.50M | -776.00K | -49.00K | -48.00K | -25.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 73.23M | 44.97M | 32.16M | 20.42M | 24.37M | 21.07M | 22.50M | 23.29M | 15.37M | 15.54M | 9.30M | 7.17M |
| General & Administrative | 13.81M | 11.80M | 10.77M | 9.62M | 9.09M | 8.92M | 9.85M | 4.23M | 5.72M | 4.71M | 4.57M | 1.51M |
| Selling & Marketing | -427.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.38M | 11.80M | 10.77M | 9.62M | 9.09M | 8.92M | 9.85M | 4.23M | 5.72M | 4.71M | 4.57M | 1.51M |
| Other Expenses | 0.00 | -2.05M | -1.23M | -231.00K | -132.00K | 756.00K | 0.00 | 3.12M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 87.04M | 54.71M | 41.70M | 29.81M | 33.32M | 30.00M | 32.35M | 27.52M | 21.09M | 20.25M | 13.87M | 8.68M |
| Cost & Expenses | 87.04M | 54.71M | 41.70M | 29.81M | 33.32M | 30.00M | 32.35M | 27.52M | 21.09M | 20.25M | 13.87M | 8.68M |
| Interest Income | 4.03M | 925.00K | 9.00K | 93.00K | 313.00K | 447.00K | 170.00K | 2.00K | 156.00K | 40.00K | 94.00K | 102.00K |
| Interest Expense | 0.00 | 54.00K | 41.00K | 39.00K | 23.00K | 19.00K | 121.00K | 1.23M | 18.00K | 4.37M | 0.00 | 0.00 |
| Depreciation & Amortization | 427.00K | 415.00K | 556.00K | 668.00K | 776.00K | 49.00K | 48.00K | 25.00K | 474.00K | 657.00K | 640.00K | 649.00K |
| EBITDA | -80.99M | -53.98M | -40.01M | -26.81M | -32.10M | -23.05M | -29.71M | -24.37M | -11.92M | -19.73M | -13.23M | -6.98M |
| EBITDA Ratio | 0.00% | 0.00% | -2,679.40% | -1,881.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -87.04M | -56.76M | -41.43M | -28.54M | -33.45M | -30.75M | -32.35M | -27.52M | -21.09M | -20.92M | -13.87M | -8.80M |
| Operating Income Ratio | 0.00% | 0.00% | -2,761.73% | -1,902.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.63M | 2.31M | 815.00K | 1.02M | 548.00K | 7.63M | 2.47M | 1.89M | 9.04M | -4.50M | -4.31M | 1.04M |
| Income Before Tax | -81.41M | -54.45M | -40.61M | -27.52M | -32.90M | -23.12M | -29.88M | -25.63M | -20.95M | -25.42M | -18.18M | -7.76M |
| Income Before Tax Ratio | 0.00% | 0.00% | -2,707.40% | -1,834.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 147.00K | -24.00K | -2.00K | -3.00K | 20.00K | -157.00K | 4.35M | 152.00K | 31.00K | 149.00K | 0.00 |
| Net Income | -81.41M | -54.60M | -40.59M | -27.51M | -32.90M | -23.14M | -29.73M | -25.63M | -21.10M | -25.45M | -18.32M | -7.76M |
| Net Income Ratio | 0.00% | 0.00% | -2,705.80% | -1,834.27% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.98 | -4.82 | -4.73 | -4.64 | -14.57 | -16.36 | -32.45 | -27.29 | -12.37 | -21.45 | -24.62 | -10.42 |
| EPS Diluted | -3.98 | -4.82 | -4.73 | -4.64 | -14.57 | -16.05 | -32.35 | -27.29 | -12.37 | -21.45 | -24.62 | -10.42 |
| Weighted Avg Shares Out | 20.45M | 11.32M | 8.58M | 5.93M | 2.26M | 1.41M | 916.18K | 939.24K | 1.71M | 1.19M | 744.40K | 744.40K |
| Weighted Avg Shares Out (Dil) | 20.45M | 11.32M | 8.58M | 5.93M | 2.26M | 1.44M | 918.86K | 939.24K | 1.71M | 1.19M | 744.40K | 744.40K |
Leap Therapeutics: What Prompted Prioritizing This Precision Oncology Company?
Shares of this small oncology company have risen by 45% over the past three months, yet are down 10% over the past month.
Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility
Check these three biotech penny stocks out for your list this month The post Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Best Short Squeeze Penny Stocks To Buy? 4 To Watch Right Now
Are these the top penny stocks to watch for a short squeeze? The post Best Short Squeeze Penny Stocks To Buy?
Leap Therapeutics: Another Leap Coming Up
Leap Therapeutics: Another Leap Coming Up
Leap Therapeutics: All On The Line
Leap Therapeutics is an early stage oncology company with a single active asset. Their single asset focuses on a pathway that is dysregulated in multiple cancers.
5 Buy-Rated, Scorching-Hot Stocks All Trading Under $10
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
3 Biotech Stocks That Surged in September
Find out why last month was a big one for these three drugmakers.
Leap Therapeutics, AstraZeneca Shares Get Boost From Cancer Presentations
Leap Therapeutics Inc. ( LPTX , Financial) lived up to its name when it scored a big jump in stock price following its presentation at the recent European Society for Medical Oncology meeting. The Cambridge, Massachusetts-based microcap saw its shares...
Leap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., Sept. 24, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of a public offering of 27,568,072 shares of its common stock, which includes the sale of...
Leap Therapeutics Announces Pricing of $90 million of Common Stock and Pre-Funded Warrants
CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of its common stock at a public offering price of $2.85...
Source: https://incomestatements.info
Category: Stock Reports